Efficacy and Safety of the Ultrasound Stimulation Device NEFRONIX in Patients With Chronic Kidney Disease
A Prospective, Multicenter, Single-arm, Open-label, Non-randomized Exploratory Clinical Trial to Evaluate the Efficacy and Safety of Glomerular Filtration Rate (GFR-EPI) Using NEFRONIX in Patients With Chronic Kidney Disease (CKD)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: SungKyung Lee
- Phone Number: 82+10-9877-8173
- Email: sklee@deepsonbio.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants who have received sufficient explanation of the study and have voluntarily provided written informed consent.
- Male and female adults aged 18 to 65 years at the time of consent.
- Participants with chronic kidney disease, defined as an estimated glomerular filtration rate (eGFR) between 20 and 60 mL/min/1.73 m².
- Participants who agree to use and maintain appropriate contraception throughout the study period.
Exclusion Criteria:
- Participants currently enrolled in another clinical study with an ongoing follow-up period.
- Participants with heart failure.
- Participants who have undergone reperfusion therapy for cardiovascular disease within the past year.
- Participants with platelet or coagulation disorders, including those receiving antithrombotic therapy.
- Participants with acute or chronic urinary tract infection.
- Participants with polycystic kidneys.
- Participants with anatomical kidney abnormalities (e.g., solitary kidney, horseshoe kidney, polycystic kidney disease) as determined by the investigator.
- Participants with urinary tract obstruction.
- Participants who have received a kidney transplant.
- Participants with kidney or urinary tract stones.
- Participants who have experienced acute kidney injury or changes in CKD stage within the past 3 months.
- Participants with serum albumin <3.0 g/dL and either 24-hour proteinuria ≥3.0 g/day or random urine protein/creatinine ratio ≥3.0 mg/mg.
- Participants with uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >100 mmHg despite treatment with two or more antihypertensive medications).
- Participants with liver dysfunction.
- Participants receiving immunosuppressive therapy.
- Participants with body mass index (BMI) >35 kg/m² or body weight <40 kg.
- Participants with a history of severe illness, such as cancer or tuberculosis.
- Participants with contact dermatitis or other significant skin sensitivities.
- Participants with fever ≥40°C (104°F) measured via tympanic temperature.
- Participants deemed unsuitable for participation in the study by the investigator for any other reason.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: NEFRONIX Treatment
Participants in this arm will receive ultrasound stimulation using the NEFRONIX G-01 device applied to the kidneys three times per week for four weeks, in accordance with the study protocol.
Standard clinical care for chronic kidney disease will be maintained throughout the study period.
|
Ultrasound stimulation will be delivered to the renal area using the NEFRONIX G-01 device.
The intervention will be administered three times per week for four weeks in accordance with the study protocol.
Standard clinical management for chronic kidney disease will be continued during the study period.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Glomerular Filtration Rate Estimated by Serum Creatinine (eGFR-EPI Cr)
Time Frame: Baseline to after 4 weeks of application of the investigational medical device
|
The primary outcome is the change in glomerular filtration rate estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation based on serum creatinine (eGFR-EPI Cr) from baseline to after 4 weeks of application of the investigational medical device.
|
Baseline to after 4 weeks of application of the investigational medical device
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in Glomerular Filtration Rate Estimated by Serum Creatinine (eGFR-EPI Cr)
Time Frame: Baseline to 12 weeks after application of the investigational medical device
|
Baseline to 12 weeks after application of the investigational medical device
|
|
Change in Glomerular Filtration Rate Estimated by Cystatin C (eGFR-EPI CysC)
Time Frame: Baseline to after 4 weeks of application of the investigational medical device
|
Baseline to after 4 weeks of application of the investigational medical device
|
|
Change in Glomerular Filtration Rate Estimated by Cystatin C (eGFR-EPI CysC)
Time Frame: Baseline to 12 weeks after application of the investigational medical device
|
Baseline to 12 weeks after application of the investigational medical device
|
|
Change in Renal Function Assessed by Tc-99m DTPA Renal Scintigraphy
Time Frame: Baseline to after 4 weeks of application of the investigational medical device
|
Baseline to after 4 weeks of application of the investigational medical device
|
|
Change in Renal Function Assessed by Tc-99m DTPA Renal Scintigraphy
Time Frame: Baseline to 12 weeks after application of the investigational medical device
|
Baseline to 12 weeks after application of the investigational medical device
|
|
Change From Baseline in Urinary Protein Excretion
Time Frame: Baseline to after 4 weeks of application of the investigational medical device
|
Baseline to after 4 weeks of application of the investigational medical device
|
|
Change From Baseline in Urinary Protein Excretion
Time Frame: Baseline to 12 weeks after application of the investigational medical device
|
Baseline to 12 weeks after application of the investigational medical device
|
|
Change From Baseline in Serum High-Sensitivity C-Reactive Protein (hsCRP) Concentration
Time Frame: Baseline to after 4 weeks of application of the investigational medical device
|
Baseline to after 4 weeks of application of the investigational medical device
|
|
Change From Baseline in Serum High-Sensitivity C-Reactive Protein (hsCRP) Concentration
Time Frame: Baseline to 12 weeks after application of the investigational medical device
|
Baseline to 12 weeks after application of the investigational medical device
|
|
Change From Baseline in Renal Resistive Index Assessed by Doppler Ultrasonography
Time Frame: Baseline to after 4 weeks of application of the investigational medical device
|
Baseline to after 4 weeks of application of the investigational medical device
|
|
Change From Baseline in Renal Resistive Index Assessed by Doppler Ultrasonography
Time Frame: Baseline to 12 weeks after application of the investigational medical device
|
Baseline to 12 weeks after application of the investigational medical device
|
|
Change From Baseline in Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) Concentration
Time Frame: Baseline to after 4 weeks of application of the investigational medical device
|
Baseline to after 4 weeks of application of the investigational medical device
|
|
Change From Baseline in Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) Concentration
Time Frame: Baseline to 12 weeks after application of the investigational medical device
|
Baseline to 12 weeks after application of the investigational medical device
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Pathologic Processes
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Chronic Disease
- Disease Attributes
- Renal Insufficiency
- Pathological Conditions, Signs and Symptoms
- Renal Insufficiency, Chronic
Other Study ID Numbers
Other Study ID Numbers
- Cenovia
- 1866 (Other Identifier: Ministry of Food and Drug Safety (MFDS))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.